In EDS ansehen

Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients

Gespeichert in:
Bibliographische Detailangaben
Titel: Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients
Autoren: Woolpert, Kirsten M., Schmidt, Julie A., Ahern, Thomas P., Hjorth, Cathrine F., Farkas, Dóra K., Ejlertsen, Bent, Collin, Lindsay J., Lash, Timothy L., Cronin-Fenton, Deirdre P.
Quelle: Breast Cancer Res
Breast Cancer Research, Vol 26, Iss 1, Pp 1-11 (2024)
Woolpert, K M, Schmidt, J A, Ahern, T P, Hjorth, C F, Farkas, D K, Ejlertsen, B, Collin, L J, Lash, T L & Cronin-Fenton, D P 2024, ' Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients ', Breast cancer research : BCR, vol. 26, no. 1, 59 . https://doi.org/10.1186/s13058-024-01819-4
Woolpert, K M, Schmidt, J A, Ahern, T P, Hjorth, C F, Farkas, D K, Ejlertsen, B, Collin, L J, Lash, T L & Cronin-Fenton, D P 2024, 'Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients', Breast Cancer Research, vol. 26, no. 1, 59, pp. 59. https://doi.org/10.1186/s13058-024-01819-4
Verlagsinformationen: Springer Science and Business Media LLC, 2024.
Publikationsjahr: 2024
Schlagwörter: Antineoplastic Agents, Hormonal/therapeutic use, Clinical characteristics, Antineoplastic Agents, Hormonal, Research, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Breast Neoplasms, Comorbidities, Medication Adherence, 3. Good health, Premenopausal breast cancer, 03 medical and health sciences, Adjuvant endocrine therapy, 0302 clinical medicine, Breast Neoplasms/drug therapy, Adherence, Chemotherapy, Adjuvant, Humans, Female, Chronic medication use, RC254-282, Retrospective Studies
Beschreibung: Introduction Patients with hormone receptor positive breast cancer are recommended at least five years of adjuvant endocrine therapy, but adherence to this treatment is often suboptimal. We investigated longitudinal trends in adjuvant endocrine therapy (AET) adherence among premenopausal breast cancer patients and identified clinical characteristics, including baseline comorbidities and non-cancer chronic medication use, associated with AET adherence. Methods We included stage I–III premenopausal breast cancer patients diagnosed during 2002–2011 and registered in the Danish Breast Cancer Group clinical database who initiated AET. We used group-based trajectory modeling to describe AET adherence patterns. We also linked patients to Danish population-based registries and fit multinomial logistic models to compute odds ratios (ORs) and 95% confidence intervals (95% CIs) associating clinical characteristics with AET adherence patterns. Results We identified three adherence patterns among 4,353 women—high adherers (57%), slow decliners (36%), and rapid decliners (6.9%). Women with stage I disease (vs. stage II; OR: 1.9, 95% CI 1.5, 2.5), without chemotherapy (vs. chemotherapy; OR: 4.3, 95% CI 3.0, 6.1), with prevalent comorbid disease (Charlson Comorbidity Index score ≥ 1 vs. 0; OR: 1.6, 95% CI 1.1, 2.3), and with a history of chronic non-cancer medication use (vs. none; OR: 1.3, 95% CI 1.0, 1.8) were more likely to be rapid decliners compared with high adherers. Conclusions Women with stage I cancer, no chemotherapy, higher comorbidity burden, and history of chronic non-cancer medication use were less likely to adhere to AET. Taking steps to promote adherence in these groups of women may reduce their risk of recurrence.
Publikationsart: Article
Other literature type
Dateibeschreibung: application/pdf
Sprache: English
ISSN: 1465-542X
DOI: 10.1186/s13058-024-01819-4
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38589932
https://doaj.org/article/091fb63dec7f4ac986c7af6f5c78c063
https://curis.ku.dk/ws/files/389507441/s13058_024_01819_4.pdf
https://pure.au.dk/portal/en/publications/34fb27c9-f015-4a7f-ada6-027499740f99
https://doi.org/10.1186/s13058-024-01819-4
http://www.scopus.com/inward/record.url?scp=85190343814&partnerID=8YFLogxK
Rights: CC BY
URL: http://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (http://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (http://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Dokumentencode: edsair.doi.dedup.....e954a765cbb28910ae55e1e3e2cd1b2e
Datenbank: OpenAIRE
Beschreibung
Abstract:Introduction Patients with hormone receptor positive breast cancer are recommended at least five years of adjuvant endocrine therapy, but adherence to this treatment is often suboptimal. We investigated longitudinal trends in adjuvant endocrine therapy (AET) adherence among premenopausal breast cancer patients and identified clinical characteristics, including baseline comorbidities and non-cancer chronic medication use, associated with AET adherence. Methods We included stage I–III premenopausal breast cancer patients diagnosed during 2002–2011 and registered in the Danish Breast Cancer Group clinical database who initiated AET. We used group-based trajectory modeling to describe AET adherence patterns. We also linked patients to Danish population-based registries and fit multinomial logistic models to compute odds ratios (ORs) and 95% confidence intervals (95% CIs) associating clinical characteristics with AET adherence patterns. Results We identified three adherence patterns among 4,353 women—high adherers (57%), slow decliners (36%), and rapid decliners (6.9%). Women with stage I disease (vs. stage II; OR: 1.9, 95% CI 1.5, 2.5), without chemotherapy (vs. chemotherapy; OR: 4.3, 95% CI 3.0, 6.1), with prevalent comorbid disease (Charlson Comorbidity Index score ≥ 1 vs. 0; OR: 1.6, 95% CI 1.1, 2.3), and with a history of chronic non-cancer medication use (vs. none; OR: 1.3, 95% CI 1.0, 1.8) were more likely to be rapid decliners compared with high adherers. Conclusions Women with stage I cancer, no chemotherapy, higher comorbidity burden, and history of chronic non-cancer medication use were less likely to adhere to AET. Taking steps to promote adherence in these groups of women may reduce their risk of recurrence.
ISSN:1465542X
DOI:10.1186/s13058-024-01819-4